🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

FDC Limited FDC NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.fdcindia.com
Company Profile ↓
₹424.30
-15.14% 1Y
Mkt Cap₹6,908.03 Cr
P/E24.54
P/B2.80
Div. Yield2.31%
52W High₹500.37
52W Low₹321.10
Book Value₹152.64
EPS (TTM)₹17.29

Company Overview

FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecology, dermatology, and analgesics in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured ORS powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Vitcofol, Ziglim, Ziglim-M,Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Electral, and Enerzal brands. It also exports its products to approximately 50 countries. FDC Limited was founded in 1936 and is based in Mumbai, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 13.2% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 24.5, below the sector median of 40.0.

Dividend Income

Offers a dividend yield of 2.31%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹2,170.93 Cr (+3.0% YoY); net profit ₹281.42 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +3.0%, earnings +5.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 6.9%, profit CAGR 13.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:6.89%
1 Year:2.98%

Compounded Profit Growth

5 Years:13.19%
1 Year:5.49%

Stock Price Performance

1 Year:-15.14%
6 Months:+6.80%
3 Months:+18.88%
1 Month:+10.27%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 58% of range
₹321.10 ₹500.37
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • Golden Cross3d ago
  • RSI (14)58.62 · Neutral
Price Performance
1M+10.27%
3M+18.88%
6M+6.80%
1Y-15.14%
Valuation vs Sector

P/E of 24.54 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Profit CAGR of 13.2% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
24.54
Industry PE
39.97
Forward P/E
18.21
PEG Ratio
-
Book Value
₹152.64
Price to Book
2.80
P/S
3.21
EV/EBITDA
18.67
Dividend Yield
2.31%

Growth (CAGR)

Revenue 5Y
6.89%
Profit 5Y
13.19%
Revenue (YoY)
2.98%
Earnings (YoY)
5.49%

Profitability & Returns

ROCE
14.86%
ROE
11.32%
ROA
9.64%
Profit Margin
12.96%
Op Margin
13.21%
Gross Margin
67.25%
EPS (Latest Qtr)
₹6.35
EPS (TTM)
₹17.29

Balance Sheet & Liquidity

Debt/Equity
0.62
Quick Ratio
2.13
Current Ratio
3.11
Debt
₹15.46 Cr
Total Assets
₹2,918.97 Cr
Current Assets
₹1,132.52 Cr
Working Capital
₹768.45 Cr

Ownership

Promoter Holding
69.95%
Chg in Prom Hold
0.30%
FII / Inst Holding
7.19%
Chg in FII Hold
-0.06%

Financial Snapshot

Enterprise Value
₹6,908.03 Cr
Total Revenue (TTM)
₹2,170.93 Cr
EBITDA
₹438.83 Cr
Free Cash Flow
₹13.89 Cr
Operating Cash Flow
₹200.45 Cr
Shares Outstanding
₹16.28 Cr
Gross Margin
67.25%
Payout Ratio
28.92%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 FDC FDC Limited NSEPHARMA 424.30 24.54 ₹6,908.03 Cr 2.31% 14.86% 11.32% 6.89% 13.19%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 435.00 Cr536.00 Cr486.00 Cr458.00 Cr462.00 Cr638.00 Cr--491.89 Cr648.41 Cr473.03 Cr464.71 Cr584.79 Cr
Cost of Revenue --------161.34 Cr209.23 Cr144.56 Cr151.55 Cr205.61 Cr
Gross Profit --------330.55 Cr439.17 Cr328.47 Cr313.15 Cr379.17 Cr
Operating Expenses 386.00 Cr414.00 Cr410.00 Cr374.00 Cr406.00 Cr492.00 Cr--292.13 Cr313.73 Cr309.85 Cr275.66 Cr287.17 Cr
Operating Income 39.00 Cr112.00 Cr66.00 Cr74.00 Cr46.00 Cr136.00 Cr--38.42 Cr125.44 Cr18.62 Cr37.50 Cr92.01 Cr
EBITDA 49.00 Cr122.00 Cr76.00 Cr84.00 Cr56.00 Cr147.00 Cr--70.06 Cr175.85 Cr54.44 Cr52.29 Cr156.25 Cr
Interest Expense 1.00 Cr1.00 Cr1.00 Cr1.00 Cr1.00 Cr1.00 Cr--1.19 Cr1.17 Cr1.15 Cr1.12 Cr1.55 Cr
Pretax Income 45.00 Cr141.00 Cr93.00 Cr98.00 Cr65.00 Cr163.00 Cr--53.31 Cr159.78 Cr38.09 Cr36.38 Cr140.35 Cr
Tax Provision 14.40 Cr31.02 Cr23.25 Cr18.62 Cr18.85 Cr44.01 Cr--14.64 Cr38.42 Cr9.72 Cr8.08 Cr36.95 Cr
Net Income 31.00 Cr110.00 Cr70.00 Cr79.00 Cr46.00 Cr119.00 Cr--38.67 Cr121.35 Cr28.37 Cr28.30 Cr103.40 Cr
Diluted EPS 1.856.624.294.872.847.31--2.387.451.751.746.35

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 888.00 Cr994.00 Cr1,013.00 Cr1,074.00 Cr1,089.00 Cr1,341.00 Cr1,331.00 Cr-1,777.83 Cr1,935.20 Cr2,108.12 Cr2,170.93 Cr
Cost of Revenue --------683.73 Cr684.25 Cr736.28 Cr710.96 Cr
Gross Profit --------1,094.09 Cr1,250.95 Cr1,371.84 Cr1,459.97 Cr
Operating Expenses 690.00 Cr765.00 Cr769.00 Cr841.00 Cr860.00 Cr1,038.00 Cr997.00 Cr-881.84 Cr952.32 Cr1,100.78 Cr1,173.11 Cr
Operating Income 160.00 Cr195.00 Cr208.00 Cr198.00 Cr196.00 Cr267.00 Cr296.00 Cr-212.25 Cr298.62 Cr271.07 Cr286.86 Cr
EBITDA 199.00 Cr229.00 Cr243.00 Cr233.00 Cr229.00 Cr304.00 Cr334.00 Cr-300.31 Cr439.68 Cr415.46 Cr438.83 Cr
Interest Expense 2.00 Cr1.00 Cr1.00 Cr1.00 Cr1.00 Cr3.00 Cr3.00 Cr-3.57 Cr3.54 Cr4.51 Cr4.99 Cr
Pretax Income 204.00 Cr232.00 Cr252.00 Cr241.00 Cr237.00 Cr320.00 Cr388.00 Cr-257.80 Cr396.22 Cr357.22 Cr374.60 Cr
Tax Provision 55.08 Cr62.64 Cr63.00 Cr67.48 Cr66.36 Cr80.00 Cr85.36 Cr-63.98 Cr91.16 Cr90.43 Cr93.18 Cr
Net Income 148.00 Cr169.00 Cr189.00 Cr174.00 Cr170.00 Cr240.00 Cr301.00 Cr-194.04 Cr305.22 Cr266.79 Cr281.42 Cr
Diluted EPS 8.339.4810.609.959.7414.0317.85-11.6718.5816.3917.29

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 1,148.00 Cr1,266.00 Cr1,468.00 Cr1,505.00 Cr1,640.00 Cr1,813.00 Cr1,956.00 Cr-2,342.94 Cr2,468.09 Cr2,713.80 Cr2,918.97 Cr
Current Assets --------1,026.91 Cr1,066.49 Cr1,088.72 Cr1,132.52 Cr
Cash & Equivalents --------23.89 Cr25.42 Cr51.47 Cr48.68 Cr
Inventory --------328.54 Cr388.89 Cr375.03 Cr355.25 Cr
Receivables --------122.65 Cr117.38 Cr108.85 Cr151.72 Cr
Total Liabilities --------361.54 Cr370.92 Cr432.72 Cr433.86 Cr
Current Liabilities --------311.56 Cr310.62 Cr361.64 Cr364.07 Cr
Long Term Debt --------56.33 L24.66 L10.97 L0
Total Debt 2.00 Cr1.00 Cr1.00 Cr1.00 Cr1.00 Cr15.00 Cr15.00 Cr-28.32 Cr20.52 Cr21.17 Cr15.46 Cr
Total Equity 937.00 Cr1,083.00 Cr1,270.00 Cr1,277.00 Cr1,446.00 Cr1,547.00 Cr1,734.00 Cr-1,982.05 Cr2,097.17 Cr2,281.08 Cr2,485.11 Cr
Shares Outstanding --------16.59 Cr16.28 Cr16.28 Cr16.28 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 128.00 Cr174.00 Cr154.00 Cr150.00 Cr112.00 Cr250.00 Cr207.00 Cr-154.91 Cr220.77 Cr317.57 Cr200.45 Cr
Investing Cash Flow -89.00 Cr-73.00 Cr-144.00 Cr21.00 Cr-121.00 Cr-98.00 Cr-77.00 Cr-11.13 Cr-17.08 Cr-199.51 Cr-109.93 Cr
Financing Cash Flow -48.00 Cr-97.00 Cr0-169.00 Cr-0-142.00 Cr-129.00 Cr--179.95 Cr-202.16 Cr-92.12 Cr-93.33 Cr
Capital Expenditure -45.00 Cr-304.00 Cr-24.00 Cr-36.00 Cr-42.00 Cr-3.00 Cr-59.00 Cr--113.09 Cr-93.39 Cr-96.72 Cr-186.56 Cr
Free Cash Flow 83.00 Cr-130.00 Cr130.00 Cr114.00 Cr70.00 Cr247.00 Cr148.00 Cr-41.82 Cr127.37 Cr220.85 Cr13.89 Cr
Net Change in Cash -9.00 Cr4.00 Cr11.00 Cr1.00 Cr-8.00 Cr10.00 Cr1.00 Cr--13.90 Cr1.53 Cr25.94 Cr-2.80 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------61.5%64.6%65.1%67.3%
Operating Margin % 18.0%19.6%20.5%18.4%18.0%19.9%22.2%-11.9%15.4%12.9%13.2%
Net Margin % 16.7%17.0%18.7%16.2%15.6%17.9%22.6%-10.9%15.8%12.7%13.0%
ROE % 15.8%15.6%14.9%13.6%11.8%15.5%17.4%-9.8%14.6%11.7%11.3%
ROCE % --------10.4%13.8%11.5%11.2%

Shareholding Pattern

Insiders
69.95%
Institutions
7.19%
Public Float
23.94%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for FDC

Google News Fri, 29 May 2026

If EPS Growth Is Important To You, FDC (NSE:FDC) Presents An Opportunity - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxOQUttd3lhSVpsZFZiQjZjUlZNTG1kSHgtbTlZM2Z3Q3M2cHRrRmY4US1NVW9US3NoMldEb0psNEJpQTdRXzJ4TktkYkhoa19CaWUyX2IxdjZ0QUNYZkE4bVQyUWtfNjdaWkh4Z0cyX0p0a1lYdk1yMGRnSTJRZ25YemJjLUNSRTFNZ0Z0R2…

Google News hu, 09 Jul 2026

This new ASX IPO has jumped 17% on its first day - The Motley Fool Australia

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxOOEJoNWotQ09LS19Zd0lzSlc2bWE4YVBlSG0zWDNtbjBPU3dFWXVrcDB0azJmWFpMYXZDUEI0MU5xNHVSd25JS3p3ZDZ1TDhOdkxWOGhqTVNtTTFMLWxqZ2ZEMUNkN2dla0xlcG1DaEFPYm94NnE0bzkzRkg3WTNvR2g5X0w0WFJvQUdz?o…

Google News hu, 09 Jul 2026

Builder rockets on ASX debut, promising dividends, data centres - AFR

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPWkZhdWRoMzN0b1NpWmFTZWxOdEY2OTlhMm5HTU8xeGRsTWZoOVFWaGo4WUZXWXZrblpjMVdFNGgzRElON1RRUF9IRENiVHdLSnhpMHVaaXMwTnRqcTJUdFJjaHpqWkNnV1Q5eVd6NGVyUHlxb2dpMWdRQ2RzeGpra3NzVkhVTHpITERJT0…

Google News Fri, 05 Jun 2026

Maharashtra FDA Seizes FDC’s Enerzal Stock; Brand Drives 18% Of Company Domestic Revenue - Sahi

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQSWloUjltVU5aRC1ycTQ0NzdEdlM2eE5OdmRSUEFEWkNWRkJXNWpQV2ZRbG5qYzhOMzBQRUpxNl82WGw4d0lZQVl3YmxOWW9lckNIQ2dCZ0xHcTRlUlFLYVNCRjJuU1MtQURVQWdHMGV6NF94Uk9CNzJEZEJfU19GM0FrUW40TzkyVnRmS1…

Google News Sat, 03 Jan 2026

FDC Ltd. Share Price Today - FDC Ltd. Stock Price Live NSE/BSE - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE1IaFA2dXZiOTk1M09mUS1wQ1h5Q18xdnVrZ2VOSkhramdSS3VBZmtOcXN3andVYW8yUEZlWHNhZWd0NDY1ckFYMUloVVNOQXdfYTBtOU1wdEN2TEVvc1U2bVB2U2dSSFJITnZSUDc5U1A?oc=5" target="_blank">FDC Ltd. Share P…

Google News Wed, 27 May 2026

FDC Limited Schedules Board Meeting on May 27, 2026 to Approve FY26 Audited Financial Results - scanx.trade

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxNZEtlTlZ1X2xLbnN5MVlIeUFpbjhtTENyeklpSXVuaDhtZ3JXOTEwUWozc05BbTl5V2FnYTlkT244bXdkektlaHA4Z2tOR29IeHFxUEhGbmVUQTJSb3pGY3FaYXMzUXRUeGVfVk5kWmFmNndjWVlBN2dkcm9yalEyRUk1LTNVZEpBS3lDTl…

FDC — Frequently Asked Questions

What is the current share price of FDC Limited (FDC)?

As of 2026-07-15 09:52 IST, FDC Limited (FDC) trades at ₹424.30 on NSE. Its 52-week range is ₹321.10 to ₹500.37.

What is the market capitalisation of FDC?

FDC Limited (FDC) has a market capitalisation of ₹6,908.03 Cr on NSE.

What is the P/E ratio of FDC?

FDC trades at a trailing price-to-earnings (P/E) ratio of 24.54. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 2.80.

Does FDC pay a dividend?

FDC Limited (FDC) currently offers a dividend yield of 2.31%.

What is the return on equity (ROE) of FDC?

FDC has a return on equity (ROE) of 11.32%. Its return on capital employed (ROCE) is 14.86%.

Is FDC a good stock to buy?

This page provides a data-driven analysis of FDC Limited (FDC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space